Processing

Please wait...

Settings

Settings

Goto Application

1. WO2011005779 - BIOMARKERS FOR THE EARLY DETECTION OF AUTOIMMUNE DISEASES

Publication Number WO/2011/005779
Publication Date 13.01.2011
International Application No. PCT/US2010/041092
International Filing Date 06.07.2010
IPC
C12Q 1/68 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
CPC
A61P 1/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
A61P 1/04
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
04for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
A61P 17/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17Drugs for dermatological disorders
A61P 19/02
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
19Drugs for skeletal disorders
02for joint disorders, e.g. arthritis, arthrosis
A61P 29/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
A61P 3/10
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
08for glucose homeostasis
10for hyperglycaemia, e.g. antidiabetics
Applicants
  • UNIVERSITY OF SOUTHERN CALIFORNIA [US]/[US] (AllExceptUS)
  • HAMM-ALVAREZ, Sarah [US]/[US] (UsOnly)
  • WU, Kaijin [US]/[US] (UsOnly)
  • EDMAN, Maria, Charlotta [SE]/[US] (UsOnly)
Inventors
  • HAMM-ALVAREZ, Sarah
  • WU, Kaijin
  • EDMAN, Maria, Charlotta
Agents
  • KONSKI, Antoinette, F.
Priority Data
61/223,69207.07.2009US
61/266,98504.12.2009US
61/328,16826.04.2010US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) BIOMARKERS FOR THE EARLY DETECTION OF AUTOIMMUNE DISEASES
(FR) BIOMARQUEURS POUR LA DÉTECTION PRÉCOCE DE MALADIES AUTO-IMMUNES
Abstract
(EN)
Provided are methods for aiding in diagnosing autoimmune diseases in a mammal, comprising contacting a sample of tear from the mammal with an antibody that specifically binds to a first polypeptide selected from the group Ctss, Ctsh, Ctsr, Ctsw, Ctsz, Ifng, Il6ra, Il10, Il10ra, Il15, Tnfa, Apo-F, or Lcn-2 or a second polypeptide selected from the group lactoperoxidase, lactoferrin or lysozyme under conditions favoring the formation of an antibody-polypeptide complex, and determining the amount of complex formed, wherein an increased formation of antibody-first-polypeptide complex or a decreased formation of antibody-second-polypeptide complex as compared to a suitable control, indicates a likely positive diagnosis of an autoimmune disease for the mammal, thereby aiding in the diagnosis. Methods of treating the autoimmune diseases are also provided.
(FR)
L'invention porte sur des procédés pour aider à diagnostiquer des maladies auto-immunes dans un mammifère, comprenant les opérations consistant à mettre en contact un échantillon de larme provenant du mammifère avec un anticorps qui se lie de façon spécifique à un premier polypeptide choisi dans le groupe Ctss, Ctsh, Ctsr, Ctsw, Ctsz, Ifng, Il6ra, Il10, Il10ra, Il15, Tnfa, Apo-F ou Lcn-2 ou un second polypeptide choisi dans le groupe lactoperoxydase, lactoferrine ou lysozyme dans des conditions favorisant la formation d'un complexe anticorps-polypeptide, et à déterminer la quantité de complexe formé, une formation accrue d'un complexe anticorps-premier polypeptide ou une formation diminuée du complexe anticorps-second polypeptide par comparaison avec un témoin approprié, indique un diagnostic positif probable d'une maladie auto-immune pour le mammifère, aidant ainsi au diagnostic. L'invention porte également sur des procédés de traitement des maladies auto-immunes.
Also published as
Latest bibliographic data on file with the International Bureau